Outsourcing

Jun 15, 2016
BioPharm International
Adopting best practices and collaborating more closely with contract research organizations can help drugs get past Phase III.
Jun 15, 2016
BioPharm International
Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.
Jun 15, 2016
BioPharm International
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.
Jun 15, 2016
BioPharm International
For successful drug delivery partnerships, it’s important to take a long-term view, focus on simple designs, and address potential payer concerns up front.
Jun 15, 2016
BioPharm International
Planning ahead is key to enabling a continuous and secure supply chain that adapts to changes in market demand.
Jun 15, 2016
BioPharm International
By BioPharm International Editors
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Jun 15, 2016
BioPharm International
By BioPharm International Editors
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Jun 10, 2016
By BioPharm International Editors
Brammer Bio establishes late-phase development and commercial manufacturing facility for advanced cell and gene therapies in Lexington, MA.
Jun 07, 2016
Uncertainty about the demand for a biologic medication can be partly mollified with some well-planned capacity outsourcing, contends a new report by ORC International sponsored by Patheon.
Jun 07, 2016
By BioPharm International Editors
The new company is the product of a merger with Formex.
native1_300x100
lorem ipsum